XCSport体育

<form id='IpqAw'></form>

<bdo id='9900U'><sup id='W7WOx'><div id='karda'><bdo id='jmNVW'></bdo></div></sup></bdo>

Be the most trusted biotech company

2025-12-03

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of nsNSCLC
2025-11-29

First Shipment of Henlius Trastuzumab to U.S.
2025-11-26

Henlius Recognized as 2024 Forbes China Go-International Series Top 30
2025-11-25

Henlius 2024 Second Scientific Advisory Board Meeting Held
2025-11-22

First Patient Dosed in Phase 3 MRCT of Dual HER2 Blockade Therapy for HER2+ GC
2025-11-20

Cancer Communications Published the Results of HLX07-ESCC201: HLX07 as monotherapy or combination therapy in ESCC
2025-11-19

Henlius to Showcase Latest Results of 5 Clinical Trails at ESMO Asia 2024
2025-11-07

Henlius and SVAX Forge Strategic Partnership in the MENAT Market
2025-11-05

Latest Research into the Differentiated Mechanisms of Action of Serplulimab Published in mAbs Journal